RxDoctor Payments Data

Alan Lichtin, MD

Hematology & Oncology · Cleveland, OHNPI 1366406456

Payments from drug & device makers

$87,333in general payments, 2019–2025

Across 31 payments — averaging $2817.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$44K
  • Principia Biopharma Inc.$26K
  • Argenx US, Inc.$9K
  • Bristol Myers Squibb$6K
  • Rigel Pharmaceuticals, Inc.$2K
  • Pfizer$1K

What the payments were for

  • Consulting fees$11,62572%
  • Speaking & faculty fees$1,2007%
  • Travel & lodging$2,52816%
  • Food & beverage$7345%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,333 in reported general payments places this provider in the 70th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$28,671
Medicare patients
342
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NexviazymeAvalglucosidase Alfa-Ngpt11$646,150
GivlaariGivosiran Sodium13$554,869
JakafiRuxolitinib Phosphate37$544,005
FabrazymeAgalsidase Beta26$472,813
CerdelgaEliglustat Tartrate14$410,674
PromactaEltrombopag Olamine11$167,863
EliquisApixaban58$42,495
XareltoRivaroxaban25$22,944
Hydroxyurea101$2,409
Anagrelide Hcl13$2,154
Imatinib Mesylate15$1,126
Acyclovir13$354
Warfarin Sodium31$344
Prednisone61$306
Lidocaine-PrilocaineLidocaine/Prilocaine22$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta$43,605$167,86311 claims
PfizerEliquis$1,150$42,49558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →